Background: This phase II study was initiated to determine the efficacy and safety of gemcitabine plus cisplatin in patients with pancreatic cancer.
Introduction
Pancreatic cancer is currently the fifth leading cause of cancer mortality [1] . While surgery is the only curative treatment, most tumors (85%-90%) are not resectable at the time of diagnosis. In untreated unresectable disease, a median survival of three to six months is observed. So far, the role of chemotherapy has been limited to disease palliation. The activity of chemotherapy in pancreatic cancer is generally considered to be modest, and most phase II clinical trials evaluating new agents have failed to identify single agents with an objective response rate consistently above 10% [2] , Moreover, survival has not been improved by chemotherapy compared with best supportive care. Of all cytostatics tested, intravenous 5-fluorouracil (5-FU) has most commonly been used, both alone and in combination with other agents.
In a randomized study, Burris et al. [3] demonstrated that gemcitabine was superior to 5-FU with regard to both survival and improvement of disease-related symptoms [4] . While the median survival achieved by gemcitabine was less than six months in this study, 18% of patients survived longer than one-year compared to a one-year survival of only 2% in patients treated with 5-FU alone [3] . Furthermore, preclinical studies have shown that gemcitabine and cisplatin, which have demonstrated activity in pancreatic cancer [5] [6] [7] [8] interact synergistically [9] . Therefore, a phase II study was initiated to determine the impact of a gemcitabine plus cisplatin combination treatment on efficacy, toxicity, and quality of life in patients with advanced pancreatic cancer.
Patients and methods

Patient selection
Patients with histologically or cytologically confirmed locally advanced (stage III,Ti_4, N|) or metastatic (stage IV,Tj^,, N O -i, Mi) pancreatic cancer were enrolled into this study. Tumor lesions were required to be bidimensionally measurable at a minimum size of I cm x I cm. Patients who had received prior chemo-or radiotherapy were not included. Other eligibility criteria were age > 18 years, life expectancy 3= 12 weeks, Karnofsky performance status > 60%, and adequate bone marrow reserve (white blood cell count > 3.5 x 10 9 /l, platelets > 100 x 10 9 /l, and hemoglobin > 100 g/1). Patients with ampullary, periampullary, bile duct cancers, endocrine tumors of the pancreas or lymphoma of the pancreas were excluded from this study. Central nervous system (CNS) metastases and second primary malignancies were also criteria for exclusion, as were inadequate liver function (bilirubin > 1.5 mg/dl, abnormal prothrombin time, and alanine trans-aminase (ALT) and aspartate transaminase (AST) levels greater than three times the normal levels in patients with no liver metastases, whereas AST and ALT levels could be up to five times the normal values in patients with known liver metastases), pregnancy or breast feeding, active infection, and serious concomitant disorders. This study was conducted according to the ethical principles stated in the Declaration of Helsinki, and was approved by the Ethics Committee of our Institute. Written informed consent was obtained from all patients before entering the study.
Study design
In this multicenter, non-randomized study, patients were treated with a combination of gemcitabine 1000 mg/m 2 (as a 30-minute i.v. infusion) on days 1, 8 and 15 and cisplatin 50 mg/m 2 (as a one-hour i.v. infusion before gemcitabine administration) on days 1 and 15 of a 28-day cycle. Patients were adequately prehydrated prior to cisplatin administration. Doses were modified based on weekly blood counts in order to maintain a tolerable toxicity profile. Doses of gemcitabine and cisplatin were reduced to 50% when the absolute granulocyte count dropped to 0.5-0.99 x 1O 9 /1 or when the platelet count decreased to 50-74 x 10 9 /l. Doses were withheld when granulocyte or platelet counts were < 0.5 x 10 9 /l or <50 x 10'/l, respectively. Patients who sustained febrile neutropenia, World Health Organization (WHO) grade 4 thrombocytopenia, or bleeding associated with thrombocytopenia received a 50% dose reduction. Doses could subsequently be increased if the 50% dose level was well tolerated. Prophylactic antiemetics were permitted, as were growth factors, if required.
Baseline and treatment assessments
Before treatment, the disease state of each patient was evaluated by full medical history, analgesic requirements, performance status, and disease-related symptoms via quality of life (QoL) measurements. They also received chest X-ray, as well as measurement of visible or palpable lesions, and were asked to complete a cancer-specific QoL questionnaire, the EORTC QLQ-C30 [10] . Other pre-treatment evaluations included a full blood count, differential blood count, and prothrombin time measurements. Blood chemistries were also measured, along with urine analysis, electrocardiogram (ECG), and vital signs.
Efficacy was assessed during treatment with limited physical examination, weight measurement, analgesic use, performance status, QoL questionnaire, and disease-related symptoms before each treatment cycle. Additionally, chest X-ray and radiological imaging were performed every other treatment cycle to demonstrate disease status. Tumor measurement was assessed using computerized tomography (CT) or magnetic resonance imaging (MRI). Patients who received at least three doses of gemcitabine and two doses of cisplatin and who had bidimensionally measurable, cytologically or histologically confirmed disease were evaluable for efficacy. Patients who discontinued treatment due to toxicity prior to receiving three doses of gemcitabine and two doses of cisplatin were also considered evaluable for efficacy.
Patients who received at least one dose of gemcitabine and cisplatin were considered evaluable for safety. A full blood count was taken on each day of treatment, and blood chemistry at the start of each cycle. Toxicity was evaluated throughout the study. Patients were discontinued from the study when the treatment was associated with unacceptable toxicities or lack of efficacy, or at the patient's or investigator's request.
Tumor assessments and toxicity were evaluated using standard WHO criteria. A complete tumor response was defined as disappearance of all clinical evidence of tumor for a minimum of four weeks. Partial response was defined as > 50% decrease in the sum of the products of two perpendicular diameters of measurable lesions for a minimum of four weeks. During this time, there must have been no increase of >25% in the size of any single lesion or the appearance of any new lesion. Stable disease was defined as a decrease of total tumor size < 50% or an increase < 25%. Progressive disease was defined as an increase in the sum of the products of the diameters of measurable lesions by > 25% or the appearance of any new lesion. 
Results
Between August 1994 and May 1996, 41 chemonaive patients were enrolled in the study from 7 centers. The median follow-up was 8.2 months. The median age of patients was 57 (range 33-74) years, and 25 patients were male. Patient characteristics at entry are summarized in Table 1 . The majority of patients (85%) had metastatic disease, with liver metastases in 71%, lymph node involvement in 15%, and lung metastases in 7% of patients. Patients presenting with only one measurable site of disease suffered from liver metastasis; however, the primary tumor had been operated on or was not measurable in its extent. Only six patients categorized with stage Illb disease were evaluated exclusively on the basis of their primary pancreatic lesions. Thirty-five patients had prior surgery, twenty-six of these for diagnostic purposes, nine for palliation. Four patients did not receive sufficient therapy to be evaluable for efficacy, one had an unconfirmed diagnosis, and one had received prior chemotherapy. All patients were evaluable for toxicity.
Tumor response
Response to treatment with gemcitabine and cisplatin is summarized in Table 2 . Of the 35 patients evaluable for response, 1 complete response (CR) and 3 partial responses (PR) were observed, for an overall response rate of 11% (95% confidence interval (95% CI): 3.2%-26.7%). One additional patient achieved CR but the response was not confirmed after one month. The patient achieving a complete response and two patients with partial response presented with liver metastases. In addition, 20 (57%) evaluable patients reported a best .9) 4(11.4) * One patient achieved a complete response, however, response confirmation after one month was not performed. response of stable disease lasting ^ 3 months. Median time to progressive disease was 4.3 months (95% CI: 3.0-5.7 months). Based on an intent-to-treat analysis for all 41 patients, the median survival time was 8.2 months (95% CI: 6.1-10.6 months), and the one-year survival rate was 27%. The survival curve is shown in Figure 1 . For evaluable patients the median survival time was 8.3 months (range 0.5-26+ months). The one-year survival rate for 35 evaluable patients was 28%, while 69% were alive at 6 months and 43% were alive at 9 months. The patient who reported a complete response was still alive 26 months after study entry, while those patients with partial responses survived to 8.5, 12, and 21 months, respectively. Extended survival was also seen in a number of patients whose best response was stable disease. Six (30%) patients with stable disease survived for at least twelve months from study entry, and three patients had survival times of fifteen, twenty-one, and twentyfour months, respectively.
Other measures of efficacy
Analgesia levels were also monitored in order to assess efficacy in this patient cohort. Of the 19 patients who had a baseline analgesia score of 1, 2, or 3, nine showed an improvement, requiring a reduced level of analgesic. Three of the eleven patients who had a baseline score of 3 (oral morphine, methadone) reported a decreased need for analgesia use to a minimum level of 0 (needing no analgesia). These improvements lasted for 70-250 days during the time of study follow-up. These patients usually discontinued analgesia consumption by the second infusion of gemcitabine. Performance status improved for 15 patients, including 6 of 8 patients who had a baseline score of 70. The performance score of one of these patients improved to 100, while another improved to 90. Thirty-eight (93%) patients completed at least one QoL questionnaire (median 3.5, range 1-10). Thirty-one patients who completed a baseline and at least one postbaseline questionnaire were included in the analysis. Mean scores of functional scales and select symptom scales are reported in Table 3 .
Overall, patients noted a worsening of their physical, role, and social functioning, but the change was only statistically significant (P < 0.05) for role functioning. Emotional functioning was slightly improved, while cognitive and global quality of life were essentially unchanged. Patients noted statistically significant (P < 0.05) improvement in pain and insomnia. Nausea/vomiting and dyspnea worsened, but the change was statistically significant (P < 0.05) only for nausea and vomiting. Responders noted marked improvement in emotional functioning, fatigue, pain, dyspnea (mean score of 0), and insomnia, but these changes were not statistically significant perhaps due to the small number of patients in this subgroup.
Laboratory toxicily
As demonstrated in Table 4 , renal and hepatic toxicity remained low during combination treatment with gemcitabine and cisplatin, with WHO grade 3-4 toxicities reported in less than 6% of patients. Hematological toxicity was moderate. Grades 3 and 4 neutropenia were observed in 10 (29%) and 2 (6%) patients, leukopenia in 2 (5%) and 0 patients, anemia in 5 (13%) and 0 patients, and thrombocytopenia in 6 (16%) and 5 (13%) patients, respectively. The clinical impact of these toxicities, however, was negligible: there was no grade 3 or 4 infection, and no bleeding episodes were reported.
Non-laboratory toxicity
As shown in Table 5 , non-laboratory toxicities with gemcitabine and cisplatin were infrequent. The most frequently reported event was nausea/vomiting, with WHO grade 3 toxicity observed in four (10%) patients and grade 4 in one (3%) patient. One (3%) patient had grade 3 diarrhea, and two (5%) had grade 3 constipation. Hair loss was uncommon with more than half the patients reporting no hair loss, and only one (3%) patient with grade > 2 alopecia (grade 3). Flu-like symptoms, which have been reported in other gemcitabine studies, were not seen in this trial.
Dose omissions and reductions
Of the 515 planned doses of gemcitabine, 103 (20%) were reduced and 56 (11%) were omitted. Thrombocytopenia was the main cause of dose reduction (63%), followed by leukopenia (15%). Thrombocytopenia was responsible for 52% of gemcitabine dose omissions. Of the 344 planned cisplatin infusions, 78 (23%) were reduced and 47 (14%) were omitted. Leukopenia was responsible for 17% of dose reductions and thrombocytopenia for 65%, while thrombocytopenia and leukopenia caused 47% and 9% of dose omissions, respectively.
Discussion
The results of this study indicate that the combination of gemcitabine and cisplatin is an attractive treatment option for patients with locally advanced or metastatic pancreatic cancer. While the overall response rate (CR + PR) of 11% was considered modest, stable disease (SD) was achieved in an additional 57% of patients. In other words, primary progression of the disease could be arrested, at least transiently, in 69% of patients. Including SD with CR and PR rates may better reflect the true benefit of chemotherapy than the classical response rate denned by CR + PR. This is especially true in pancreatic cancer, in which conventional imaging procedures show classical tumor response only late during the course of effective therapy [2, 11] . In this study, PR + CR were observed in four patients after treatment with 4, 6, 10, and 10 cycles, respectively. The importance of stable disease as a reasonable treatment goal is further emphasized by the observation that 30% of patients with SD in this study survived longer than one year. The positive impact of the gemcitabine plus cisplatin combination treatment on tumor response is well supported by a median survival of 8.2 months. This compares favorably to a median survival of five months reported for each of three arms in a large randomized trial comparing FAM (5-FU, doxorubicin, and mitomycin-C), FA (5-FU, doxorubicin), and bolus 5-FU singleagent treatment [12] . Two randomised studies analysed the activity of single-agent gemcitabine in pancreatic cancer. One study demonstrated a significantly (P = 0.0025) longer overall survival for patients treated with gemcitabine (5.65 months) as compared to 5-FU (4.41 monts) [3] . These data were confirmed by another trial showing again a significant (P = 0.0001) survival advantage for patients treated with single-agent gemcitabine (6.4 months) as compared to the matrix metalloproteinase inhibitor BAY12-9566 (3.2 months) [13] . By comparison, a median survival of 4.8 months (95% CI: 4.5-5.1 months) was observed in 2,380 patients treated with gemcitabine alone in a treatment investigational new drug program [14] .
While 5-FU alone resulted in a one-year survival of only 2%, single-agent gemcitabine [3] and gemcitabine plus cisplatin resulted in 18% and 27% one-year survival rates, respectively. These higher rates achieved with gemcitabine alone and with gemcitabine-cisplatin are impressive in that one-year survival, rather than median survival, better represents the life gained in responding patients.
The comparatively long survival observed in our study may best be explained by the fact that a considerable number of patients (57%) had stable disease for ^ 3 months, with a median time to progressive disease of 4.3 months. Of the patients with stable disease, six patients with stable disease survived for one year or more after start of treatment.
Additional efficacy assessments carried out in this study were improvement of disease-related symptoms reflected by the results from the QoL questionnaire, and changes from baseline in analgesic use and performance status. Disease-related symptom improvement was reported in 17% of patients after three cycles of gemcitabine treatment. The remaining 83% did not show an improvement in clinical status; however, the median survival of these patients was only 4.6 months. Nearly three-quarters of the patients noticed an improvement in pain, with a reduction or even omission of their analgesic requirements.
The gemcitabine plus cisplatin combination was rather well tolerated. Only five patients experienced WHO grade 3 or 4 toxicity, and no patients were discontinued from the study due to treatment-related toxicity. Hematological toxicity was moderate; only two patients experienced WHO grade 4 neutropenia and five patients experienced grade 4 thrombocytopenia. However, this was not accompanied by bleeding complications or severe infectious episodes. Thrombocytopenia was the main reason for reductions in cisplatin and gemcitabine doses, most of which occurred on day 15. Eleven percent of gemcitabine and 14% of cisplatin infusions had to be omitted, indicating that the treatment schedule chosen should not be intensified further.
There were only five cases of grade 3-4 nausea/ vomiting, which were easily managed with standard antiemetics.
Other non-hematological toxicity was particularly infrequent and less than what was expected. Only one patient showed cisplatin-induced alopecia, and there were no reports of gemcitabine-induced flu-like symptoms. Pulmonary toxicity was not observed. A possible explanation for this low incidence of side effects might be the regular co-medication of dexamethasone for prevention of cisplatin-induced nausea and vomiting.
In summary, the combination of gemcitabine and cisplatin is a promising treatment option for patients with locally advanced and metastatic pancreatic cancer. The combination treatment may be performed with few severe toxicities and without compromising quality of life. The favorable efficacy and mild toxicity profile of gemcitabine and cisplatin, together with the improvement of disease-related symptoms, analgesic use, and performance status, warrants further examination of this combination in a larger patient group. Therefore, a randomized phase III trial has been initiated to compare the combination of gemcitabine and cisplatin versus single-agent treatment with gemcitabine in patients with pancreatic cancer.
